New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent SNY news | >>
October 29, 2014
10:00 EDTSNYOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:19 EDTSNYOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Goodyear Tire (GT), up 10%... Electronic Arts (EA), up 3.7%... ZELTIQ (ZLTQ), up 9%... Eaton (ETN), up 2.3%... Anadarko (APC), up 2%... U.S. Steel (X), up 7.7%... IAC (IACI), up 3.6%. ALSO HIGHER: Fiat Chrysler (FCAU), up 12% after reporting quarterly results, announcing plan to spin off Ferrari... Cara Therapeutics (CARA), up 17.8% after HAL trial of IV formulation of CR845 met primary endpoint... Jamba (JMBA), up 4% after upgraded at Wedbush. DOWN AFTER EARNINGS: Facebook (FB), down 5.7%... Gilead (GILD), down 3.2%... Ralph Lauren (RL), down 2.3%... SodaStream (SODA), down 3%... Garmin (GRMN), down 5%... Applied Micro Circuits (AMCC), down 9.9%... STMicroelectronics (STM), down 10%... Ballard Power (BLDP), down 8.7%... Hershey (HSY), down 3.3%... Deutsche Bank (DB), down 2.3%... McKesson (MCK), down 2%. ALSO LOWER: Sanofi (SNY), down 5.7% after downgraded at various firms including Barclays and BofA/Merrill after the company's board removed Christopher Viehbacher as CEO... InvenSense (INVN), down 22%, downgraded at Pacific Crest, Northland and Piper Jaffray following the company's Q2 earnings results... CareTrust REIT (CTRE), down 3.6% after acquiring Cross Healthcare Seniors housing portfolio... Orbital (ORB), down 16% after Orb-3 launch mishap... American Realty (ARCP), down 22% after announcing resignations of CFO, CAO.
06:00 EDTSNYSanofi downgraded to Neutral from Buy at BofA/Merrill
Subscribe for More Information
05:29 EDTSNYSanofi downgraded to Hold from Buy at Deutsche Bank
Subscribe for More Information
05:28 EDTSNYSanofi downgraded to Equal Weight from Overweight at Barclays
Subscribe for More Information
05:28 EDTSNYSanofi downgraded to Hold from Buy at Jefferies
Jefferies downgraded Sanofi to Hold following the company's Q3 results.
05:27 EDTSNYSanofi board removes Christopher Viehbacher as CEO
Subscribe for More Information
October 28, 2014
10:53 EDTSNYSanofi sees pricing pressure, competition in diabetes sector
Subscribe for More Information
09:20 EDTSNYOn The Fly: Pre-market Movers
Subscribe for More Information
05:40 EDTSNYSanofi reports Q3 business EPS EUR 1.47 vs. EUR 1.36 last year
Subscribe for More Information
October 27, 2014
07:23 EDTSNYAmerican College of Surgeons holds a conference
Subscribe for More Information
07:21 EDTSNYSanofi board explains CEO development not included in meeting, Reuters says
Subscribe for More Information
October 22, 2014
07:35 EDTSNYCardiometabolic Health Congress to hold annual meeting
Subscribe for More Information
October 21, 2014
07:06 EDTSNYFierce Biotech to hold a breakfast meeting
Subscribe for More Information
06:44 EDTSNYActavis among bidders for Omega Pharma, Bloomberg reports
Subscribe for More Information
October 20, 2014
10:37 EDTSNYSanofi unit announces Aubagio gains FDA approval due to study data
Genzyme, a Sanofi company, announced that the Food and Drug Administration has approved the inclusion of efficacy and safety data from the TOWER and TOPIC studies of once-daily, oral Aubagio in the productís U.S. label. In the TOWER study, patients with relapsing MS receiving Aubagio 14 mg had a statistically significant reduction in annualized relapse rate and relative risk of sustained disability progression compared to placebo. In addition, a significant reduction in annualized relapse rate was observed in patients treated with Aubagio 7 mg compared to placebo. The TOPIC study was designed to assess whether initiation of Aubagio in patients who experienced their first neurological symptoms suggestive of MS could prevent or delay a second clinical attack. In this study, the proportion of patients free of relapse was statistically significantly greater for Aubagio 14 mg and 7 mg, compared to placebo. Results of the TOPIC study were published in The Lancet Neurology in September.
08:06 EDTSNYMerck, Sanofi unit announce pediatric hexavalent vaccine BLA
Subscribe for More Information
07:19 EDTSNYIBC Life Sciences to hold a conference
Subscribe for More Information
07:10 EDTSNYAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
07:02 EDTSNYRegeneron Sanofi begins dosing in Phase 3 study of dupilumab
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis, or AD, that is not adequately controlled with topical AD medications. LIBERTY AD CHRONOS, the first trial in the Phase 3 clinical program for dupilumab, is a randomized, double-blind, placebo-controlled, multi-national study with the primary objective of demonstrating the efficacy of dupilumab in adults with moderate to severe AD when administered concomitantly with topical corticosteroids through 16 weeks.
1 | 2 | all recent SNY news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use